Investigators reported that in the phase III, multicenter Lp(a) HORIZON trial pelacarsen lowered Lp(a) levels by an average of 78% across participants, yet there was no change in the trial’s primary clinical outcome. The primary endpoint measured time to first major adverse cardiovascular event (MACE), defined as nonfatal myocardial infarction, nonfatal stroke, urgent coronary revascularization or cardiovascular death. Both the primary analysis (participants with Lp(a) ≥70 mg/dL) and the prespecified subgroup with Lp(a) ≥90 mg/dL showed neutral results — no difference in time to MACE between pelacarsen and placebo.
The trial began in 2019 and completed in 2026 at 797 sites across 42 countries. Investigators screened 14,249 adults and enrolled 8,323 with established cardiovascular disease and baseline Lp(a) ≥70 mg/dL; the median enrollment Lp(a) was 109 mg/dL. Randomization assigned participants to monthly subcutaneous injections of pelacarsen 80 mg or placebo. At enrollment, participants underwent 30–90 days of optimization of guideline-directed therapies for blood pressure and cholesterol if required. About 77–78% of participants were on high-intensity statins and nearly all were on antiplatelet therapy. The cohort’s mean age was 60 years; 27% were women and roughly 26% had diabetes.
Overall serious adverse event rates were similar between groups across the seven-year study period. However, pelacarsen-treated patients experienced higher rates of certain adverse reactions than placebo-treated patients, specifically flu-like symptoms, injection-site reactions and acute allergic reactions. The most severe allergic events—anaphylaxis—were reported in 19 pelacarsen recipients and in none of the placebo group; no deaths were attributed to these allergic reactions. Medication discontinuation because of adverse reactions occurred in about 21% of pelacarsen patients versus more than 7% in the placebo arm.
The study team performed extended analyses that evaluated several combinations of cardiovascular outcomes and secondary endpoints, including heart attack, stroke or cardiovascular death; heart attack, urgent revascularization or death from coronary heart disease; change in Lp(a) from baseline to one year; and all-cause mortality. Across these extended endpoints and across prespecified subgroups (stratified by baseline Lp(a), LDL-C, hs-CRP and time from qualifying event), outcomes were consistent and neutral between pelacarsen and placebo. Investigators reported no trend toward benefit in any subgroup, including the participants with the highest baseline Lp(a) values.
Lead author Steven E. Nissen, M.D., FAHA, and colleagues described the result as surprising and disappointing: substantial biochemical lowering of Lp(a) did not translate into a measurable reduction in cardiovascular events in this trial. The authors emphasized that these neutral trial results do not invalidate Lp(a) as a cardiovascular risk factor. They recommended continued measurement of Lp(a) to inform risk assessment and preventive strategies and urged participants to remain enrolled in other ongoing Lp(a) outcome trials. The report also noted that three additional cardiovascular outcome trials targeting high Lp(a) are underway, each testing different investigational approaches, and that their results will be important to contextualize the HORIZON findings.
The investigators listed several limitations that affect interpretation. Some qualifying cardiovascular events occurred during the COVID-19 pandemic and could not be definitively classified as COVID-related, which may have influenced event patterns. The trial population lacked broad racial and ethnic diversity: 78% self-identified as White, and under 4% were of African ancestry, a group known to have higher average Lp(a) levels. The study team noted that future trials need more inclusive recruitment to assess efficacy and safety across varied populations. Funding for Lp(a) HORIZON came from Novartis, and co-author disclosures are contained in the full manuscript. The investigators closed by calling for additional mechanistic and clinical research to define how Lp(a) reduction may or may not alter cardiovascular risk and by pointing to the ongoing outcome trials as the next steps to resolve remaining questions.